Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 33
  1. Apr 16, 2026 · 07:00 · BLCO · Routine +

    Bausch + Lomb ESG Push Overshadows Flat Margins as Debt Refinancing Looms

    Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

    01
  2. Apr 16, 2026 · 07:00 · ZYUS · Routine +

    ZYUS Life Sciences Clears Phase 2a Enrollment Hurdle as Capital Constraints Persist

    ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

    02
  3. Apr 16, 2026 · 07:00 · MRVL · Routine +

    Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

    Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders

    03
  4. Apr 16, 2026 · 05:48 · 4568 · Routine +

    Daiichi Sankyo Partnership Validates MNM Platform but Financial Terms Remain Opaque

    Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies

    04
  5. Apr 15, 2026 · 17:31 · MDP · Routine +

    Medexus Confirms Cash Flow Accretion as GRAFAPEX Commercialization Accelerates

    Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation

    05
  6. Apr 15, 2026 · 17:30 · COV · Routine +

    Covalon Stabilizes Post-Dividend with Operational Momentum Despite Revenue Contraction

    Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care

    06
  7. Apr 15, 2026 · 08:02 · BPC · Neutral

    Management Spending on Marketing and Advisory Signals Operational Expansion Without Immediate Revenue Catalyst

    The Precision Peptide Company Announces Public Relations and Consulting Services Agreement

    07
  8. Apr 15, 2026 · 08:00 · MVMD · Routine +

    MVMD Closes Financing to Fuel Agrarius Commercialization Amid Dilutive Share Issuance

    Mountain Valley MD Announces Closing of Non-Brokered Private Placement of Units and Concurrent Shares for Debt Transactions

    08
  9. Apr 15, 2026 · 07:01 · FNDX · Routine +

    FendX Pivots Manufacturing Strategy Amidst Partnership Exit

    FendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface Coating

    09
  10. Apr 15, 2026 · 07:00 · MBX · Neutral

    Microbix Biosystems Showcases HCV Mimetic as Revenue Contracts Shrink and Cash Burn Accelerates

    Microbix Exhibiting & Presenting at ESCMID Global 2026

    10
  11. Apr 15, 2026 · 04:40 · 4174 · Routine +

    Advancing Glycan-based ADC Technology

    OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies

    11
  12. Apr 14, 2026 · 19:59 · OPEN · Routine +

    SPAC Merger Finalized Amidst Significant Valuation Compression

    Opensesame signs definitive agreement to acquire Vector

    12
  13. Apr 14, 2026 · 18:45 · IOT · Routine +

    Innovotech Expands U.S. Access Following Profitable FY25 Turnaround

    Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors

    13
  14. Apr 14, 2026 · 17:35 · CYTO · Routine −

    Cytophage Sheds COO as Cash Burn Forces Strategic Review

    Cytophage Announces Departure of Chief Operating Officer

    14
← Newer Older →